Dual GLP-1 Peptide Formulation pH Optimization

The patent applies parameter changes by optimizing the pH to a specific range of 7.0-8.5, which resolves the contradiction between stability and solubility. This pH range was determined through experimental evaluation to provide both adequate solubility and stability for the dual GLP-1/glucagon receptor agonist peptide, avoiding the sub-optimal solubility at lower pH values while preventing degradation at higher pH values.

The patent resolves this contradiction by establishing an optimal pH window of 7.0-8.5 through systematic parameter optimization. Experimental data showed that peptides at pH values above 8.5 exhibited reduced stability, so the formulation specifies pH 7.0-8.5 to maintain both solubility and stability, representing a balanced parameter setting that avoids both extremes.

The patent employs intermediary substances including antioxidants and surfactants in the formulation to prevent fibrillation and aggregation at therapeutic peptide concentrations. These additives act as mediators that protect the peptide from harmful interactions while maintaining the required concentration for efficacy, thereby resolving the contradiction between dosing requirements and physical stability.

The patent applies parameter changes by specifying precise formulation parameters including pH 7.0-8.5, buffer composition, and excipient concentrations to ensure liquid formulation stability. These controlled parameters enable both liquid state for easy self-administration and manufacturing reproducibility, resolving the contradiction between ease of operation and manufacturing precision.